Ligand id: 9807

Name: TNT009

1. Eskandary F, Jilma B, Mühlbacher J, Wahrmann M, Regele H, Kozakowski N, Firbas C, Panicker S, Parry GC, Gilbert JC et al.. (2018)
Anti-C1s monoclonal antibody BIVV009 in late antibody-mediated kidney allograft rejection-results from a first-in-patient phase 1 trial.
Am. J. Transplant., 18 (4): 916-926. [PMID:28980446]
2. Mühlbacher J, Jilma B, Wahrmann M, Bartko J, Eskandary F, Schörgenhofer C, Schwameis M, Parry GC, Gilbert JC, Panicker S et al.. (2017)
Blockade of HLA Antibody-Triggered Classical Complement Activation in Sera From Subjects Dosed With the Anti-C1s Monoclonal Antibody TNT009-Results from a Randomized First-in-Human Phase 1 Trial.
Transplantation, 101 (10): 2410-2418. [PMID:28926521]
3. Panicker S, Parry G. (2016)
Humanized anti-c1s antibodies and methods of use thereof.
Patent number: WO2016164358A1. Assignee: True North Therapeutics, Inc.. Priority date: 06/04/2015. Publication date: 05/04/2016.
4. Wahrmann M, Mühlbacher J, Marinova L, Regele H, Huttary N, Eskandary F, Cohen G, Fischer GF, Parry GC, Gilbert JC et al.. (2017)
Effect of the Anti-C1s Humanized Antibody TNT009 and Its Parental Mouse Variant TNT003 on HLA Antibody-Induced Complement Activation-A Preclinical In Vitro Study.
Am. J. Transplant., 17 (9): 2300-2311. [PMID:28251805]